These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31751455)

  • 1. A comparison of contemporary versus older studies of aspirin for primary prevention.
    Moriarty F; Ebell MH
    Fam Pract; 2020 Jul; 37(3):290-296. PubMed ID: 31751455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
    Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Kandala NB; Grove A; Gurung B; Morrow S; Clarke A
    Health Technol Assess; 2013 Sep; 17(43):1-253. PubMed ID: 24074752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin for Primary Prevention of Cardiovascular Events.
    Abdelaziz HK; Saad M; Pothineni NVK; Megaly M; Potluri R; Saleh M; Kon DLC; Roberts DH; Bhatt DL; Aronow HD; Abbott JD; Mehta JL
    J Am Coll Cardiol; 2019 Jun; 73(23):2915-2929. PubMed ID: 31196447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis.
    Wang M; Yu H; Li Z; Gong D; Liu X
    Am J Cardiovasc Drugs; 2022 Nov; 22(6):657-675. PubMed ID: 35570250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases in the Context of Contemporary Preventive Strategies.
    Shah R; Khan B; Latham SB; Khan SA; Rao SV
    Am J Med; 2019 Nov; 132(11):1295-1304.e3. PubMed ID: 31153866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of aspirin on mortality in the primary prevention of cardiovascular disease.
    Raju N; Sobieraj-Teague M; Hirsh J; O'Donnell M; Eikelboom J
    Am J Med; 2011 Jul; 124(7):621-9. PubMed ID: 21592450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.
    Gelbenegger G; Postula M; Pecen L; Halvorsen S; Lesiak M; Schoergenhofer C; Jilma B; Hengstenberg C; Siller-Matula JM
    BMC Med; 2019 Nov; 17(1):198. PubMed ID: 31679516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis.
    Butalia S; Leung AA; Ghali WA; Rabi DM
    Cardiovasc Diabetol; 2011 Apr; 10():25. PubMed ID: 21453547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials.
    Barbarawi M; Kheiri B; Zayed Y; Gakhal I; Al-Abdouh A; Barbarawi O; Rashdan L; Rizk F; Bachuwa G; Alkotob ML
    High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):283-291. PubMed ID: 31280451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
    ; Baigent C; Blackwell L; Collins R; Emberson J; Godwin J; Peto R; Buring J; Hennekens C; Kearney P; Meade T; Patrono C; Roncaglioni MC; Zanchetti A
    Lancet; 2009 May; 373(9678):1849-60. PubMed ID: 19482214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Liu S; Eckstein J; Lam A; Cheema AN
    Curr Vasc Pharmacol; 2023; 21(2):111-119. PubMed ID: 36718966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis.
    Lotrionte M; Biasucci LM; Peruzzi M; Frati G; Giordano A; Biondi-Zoccai G
    Prog Cardiovasc Dis; 2016; 58(5):495-504. PubMed ID: 26851562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
    Wolff T; Miller T; Ko S
    Ann Intern Med; 2009 Mar; 150(6):405-10. PubMed ID: 19293073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials.
    Mahmoud AN; Elgendy AY; Rambarat C; Mahtta D; Elgendy IY; Bavry AA
    PLoS One; 2017; 12(4):e0175283. PubMed ID: 28403216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.
    Joseph P; Roshandel G; Gao P; Pais P; Lonn E; Xavier D; Avezum A; Zhu J; Liu L; Sliwa K; Gamra H; Bangdiwala SI; Teo K; Diaz R; Dans A; Lopez-Jaramillo P; Prabhakaran D; Castellano JM; Fuster V; Rodgers A; Huffman MD; Bosch J; Dagenais GR; Malekzadeh R; Yusuf S;
    Lancet; 2021 Sep; 398(10306):1133-1146. PubMed ID: 34469765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin for primary prevention of stroke in individuals without cardiovascular disease-A meta-analysis.
    Judge C; Ruttledge S; Murphy R; Loughlin E; Gorey S; Costello M; Nolan A; Ferguson J; Halloran MO; O'Canavan M; O'Donnell MJ
    Int J Stroke; 2020 Jan; 15(1):9-17. PubMed ID: 31237833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A long-term risk-benefit analysis of low-dose aspirin in primary prevention.
    Wu IC; Hsieh HM; Yu FJ; Wu MC; Wu TS; Wu MT
    Eur J Clin Invest; 2016 Feb; 46(2):130-40. PubMed ID: 26640116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
    Berger JS; Roncaglioni MC; Avanzini F; Pangrazzi I; Tognoni G; Brown DL
    JAMA; 2006 Jan; 295(3):306-13. PubMed ID: 16418466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.
    Gallagher H; Dumbleton J; Maishman T; Whitehead A; Moore MV; Fuat A; Fitzmaurice D; Henderson RA; Lord J; Griffith KE; Stevens P; Taal MW; Stevenson D; Fraser SD; Lown M; Hawkey CJ; Roderick PJ
    Trials; 2022 Apr; 23(1):331. PubMed ID: 35449015
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.